1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,730 | 2,860 | 12.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | 353 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 02.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 431 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 30.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 350 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
30.06.2026 / 13:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.06. | EMA committee issues negative opinion on MaaT Pharma's MaaT013 | 4 | Investing.com | ||
| 26.06. | MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease | 1.116 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013... ► Artikel lesen | |
| 11.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 312 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
11.06.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | 956 | Business Wire | MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen | |
| 20.05. | MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease | 924 | Business Wire | During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.05. | MaaT Pharma to Hold Annual General Meeting on June 16, 2026 | 411 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 21.04. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | 370 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 01.04. | MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal | 555 | Business Wire | CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy
Results... ► Artikel lesen | |
| 31.03. | MaaT Pharma Announces 2025 Annual Results and Provides Business Updates | 654 | Business Wire | Potential Pivotal Year for MaaT013 (Xervyteg):
Marketing Authorization Application (MAA) in Europe for MaaT013 (Xervyteg) submitted to the European Medicines Agency (EMA) in June 2025
... ► Artikel lesen | |
| 23.03. | MaaT Pharma presents phase 3 trial results for aGvHD treatment | 2 | Investing.com | ||
| 23.03. | MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation | 468 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 09.03. | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 726 | Business Wire | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| 03.02. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 467 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 20.01. | MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis | 735 | Business Wire | IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease... ► Artikel lesen | |
| 10.12.25 | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 538 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 08.12.25 | MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival | 852 | Business Wire | Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease... ► Artikel lesen | |
| 19.11.25 | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 487 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
19.11.2025 / 11:11 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 55,40 | -1,07 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| BRAIN BIOTECH | 2,810 | -0,71 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech erhält von Royalty Pharma eine bedeutende Meilensteinzahlung in Höhe von 11,51 Millionen Euro | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Bedeutende Verträge/Sonstiges
BRAIN Biotech AG erhält von Royalty Pharma eine bedeutende Meilensteinzahlung in Höhe von 11... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,160 | +0,40 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| KUROS BIOSCIENCES | 19,580 | +1,77 % | Kuros Biosciences: Wie MagnetOs das Medizintechnologie-Portfolio stärkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -2,05 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,245 | 0,00 % | Microbot Medical Inc.: Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter | Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Emyria vor Meilenstein: Erste Sydney-Klinik ist startbereit für Psychdelika-Patienten | ||
| IMMATICS | 7,615 | +0,33 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,360 | -0,94 % | Iovance auf Wells-Fargo-Konferenz: Umsatzdynamik von AMTAGVI beflügelt Ausblick | ||
| BEONE MEDICINES LTD ADR | 296,00 | -1,33 % | BEONE MEDICINES (06160): REMINDER LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | ||
| BIOMERIEUX | 70,00 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| CYBIN | 11,320 | +1,07 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | XFRA BX20: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOXCEL THERAP.INC.NEW... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,853 | 0,00 % | Bio Green Med Solution, Inc. - S-4/A, Registration of securities, business combinations | ||
| PDS BIOTECHNOLOGY | 0,262 | +3,15 % | PDS Biotech raises up to $22.55M in PIPE financing; shares surge premarket |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,660 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.